Duloxetine Capsule, Delayed Release
Product Images NDC 71335-0402

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71335-0402). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine Fig1

A Kaplan-Meier curve comparing proportion of patients with relapse over time in days from randomization for Duloxetine versus placebo. The x-axis shows time from randomization to relapse (days) and the y-axis shows the proportion of patients with relapse, with Duloxetine showing a lower relapse proportion over the course of approximately 200 days compared to placebo.*

FDA Label Image

Duloxetine Fig10

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It compares Duloxetine 60/120 mg once daily with placebo, illustrating that a higher percentage of patients improved on Duloxetine across various levels of pain improvement.*

FDA Label Image

Duloxetine Fig2

A Kaplan-Meier survival curve chart showing the proportion of patients with relapse over time (days) from randomization. The graph compares two treatments: Duloxetine and placebo. The x-axis represents time in days up to 300, and the y-axis shows the proportion of patients with relapse from 0.0 to 1.0. The Duloxetine treatment curve is consistently lower, indicating fewer relapses compared to placebo.*

FDA Label Image

Duloxetine Fig3

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo groups. The graph compares pain improvement across these treatments with distinct markers for each group.*

FDA Label Image

Duloxetine Fig4

A line graph illustrating the percentage of patients improved based on percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo. The y-axis shows the percentage of patients improved, while the x-axis shows percent improvement in pain from baseline.*

FDA Label Image

Duloxetine Fig5

A line graph showing percent improvement in pain from baseline (x-axis) versus the percentage of patients improved (y-axis). It compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, illustrating how patient improvement varies with pain reduction percentages.*

FDA Label Image

Duloxetine Fig6

A line graph depicting the percentage of patients improved against percent improvement in pain from baseline. It compares Duloxetine at 120 mg, 60 mg, and 20 mg once daily doses with placebo, showing higher patient improvement percentages for Duloxetine doses compared to placebo across various pain improvement thresholds.*

FDA Label Image

Duloxetine Fig8

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline. Two data series are shown: Placebo (dashed line with x markers) and Duloxetine 60/120 mg once daily (solid line with diamond markers). The x-axis represents percent improvement in pain from baseline, ranging from >0 to 100. The y-axis indicates percentage of patients improved, ranging from 0 to 100.*

FDA Label Image

Duloxetine Fig9

A line graph comparing percentage of patients improved by percent improvement in pain from baseline (BOCF) between placebo and Duloxetine 60 mg once daily. The graph shows two curves, one for placebo and one for Duloxetine 60 mg, plotting patients' improvement percentages across various pain improvement thresholds from >0 to 100 percent.*

FDA Label Image

Duloxetine-structure (Duloxetine Structure)

Chemical structure of Duloxetine hydrochloride, illustrating its molecular framework with a naphthalene and thienyl group, a chiral center, and a hydrochloride moiety.*

FDA Label Image

Label Image (Lbl713350402)

Duloxetine DR 60 mg delayed release capsules label from Bryant Ranch Prepack. The label identifies the capsules as white and blue, containing 60 mg of duloxetine. It compares to Cymbalta 60 mg capsule by Ajanta Pharma Limited and includes storage instructions and warnings about drowsiness and keeping drugs out of reach of children. The package size is 30 capsules with NDC 71335-0402.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.